Natalia Pérez-Macías

Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial

Alberto M. Borobia, Antonio J. Carcas, Mayte Pérez‐Olmeda et al. · The Lancet · 2021 · 384 citations · Full text

Encoded Library Technology as a Source of Hits for the Discovery and Lead Optimization of a Potent and Selective Class of Bactericidal Direct Inhibitors of <i>Mycobacterium tuberculosis</i> InhA

Lourdes Encinas, Heather P. O’Keefe, Margarete Neu et al. · Journal of Medicinal Chemistry · 2014 · 118 citations · Full text

Bioorganic Chemistry, Hit Identification, Pharmaceutical Chemistry +22

Practical preparation of challenging amides from non-nucleophilic amines and esters under flow conditions

Johannes Vrijdag, Francisca Delgado, Nerea Alonso et al. · Chemical Communications · 2014 · 54 citations

Cannabinoid agonists showing BuChE inhibition as potential therapeutic agents for Alzheimer's disease

Pedro González-Naranjo, Natalia Pérez-Macías, Nuria E. Campillo et al. · European Journal of Medicinal Chemistry · 2013 · 50 citations · Full text

Cannabis Use, Psychoactive Drug, Alzheimer's Disease +15

Indazolylketones as new multitarget cannabinoid drugs

Pedro González-Naranjo, Natalia Pérez-Macías, Concepción Pérez et al. · European Journal of Medicinal Chemistry · 2019 · 20 citations · Full text

Cannabis Use, Psychoactive Drug, Medicine +5